Serious Adverse Events with Bevacizumab or Ranibizumab for Age-Related Macular Degeneration: Meta-analysis of Individual Patient Data

Our findings support the absence of large differences in risk of systemic SAEs between these 2 anti-VEGF drugs (i.e., relative risks of ≥1.5 are unlikely). Because additional head-to-head trials are unlikely, any further investigation of differential risk between anti-VEGF agents will be achieved only through postmarketing surveillance or through the interrogation of health-care databases.